Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients
Recruiting · NCT06389552 · Observational (researchers observe without assigning treatment) · Lead sponsor: HK inno.N Corporation
View the official record on ClinicalTrials.gov →What this trial is about
This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.
Who can take part
Age range
19 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age over 19 at the time of obtaining the informed consent form
- Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery
- ECOG 0 or 1
- Scheduled to RO or R1 resection
- Organ function capable of chemotherapy
Exclusion criteria
- FOLFIRINOX contraindications among the drug approval requirements
- Palliative Therapy
- Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX
Where it is running
1 location listed.
- Seoul ST. Mary's Hospital - Seoul, South Korea